

Veterans' Entitlements (Statements of Principles—Cumulative Equivalent Dose) Amendment Determination 2017

(No. 58 of 2017)

The Repatriation Medical Authority makes the following determination.

Dated 18 August 2017

The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of:

Professor Nicholas Saunders AO

Chairperson

Contents

	1	Name	3
	2	Commencement	
	3	Authority	
	4	Schedules	
Sche	dule 1.	—Amendments	
Sene	Part 1—Amendments of clause 9 of certain Statements of Principles		
		—Amendments of clause 1 of Schedule 1 to certain Statements of Principles	

1 Name

This instrument is the Veterans' Entitlements (Statements of Principles—Cumulative Equivalent Dose) Amendment Determination 2017 (No. 58 of 2017).

2 Commencement

This instrument commences on 18 September 2017.

3 Authority

This instrument is made under section 196B of the *Veterans' Entitlements Act 1986*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

Part 1—Amendments of clause 9 of certain Statements of Principles

1. Amendments of definition

Omit the definition of **"cumulative equivalent dose"** in clause 9 of the Statements of Principles to be amended as listed in paragraph 2 of this Part and substitute the following:

"cumulative equivalent dose" means the total dose of ionising radiation received by the particular organ or tissue from external exposure, internal exposure or both, apart from normal background radiation exposure in Australia, calculated in accordance with the methodology set out in *Guide to calculation of 'cumulative equivalent dose' for the purpose of applying ionising radiation factors contained in Statements of Principles determined under Part XIA of the Veterans' Entitlements Act 1986 (Cth)*, Australian Radiation Protection and Nuclear Safety Agency, as in force on 2 August 2017;

Note 1: Examples of circumstances that might lead to exposure to ionising radiation include being present during or subsequent to the testing or use of nuclear weapons, undergoing diagnostic or therapeutic medical procedures involving ionising radiation, and being a member of an aircrew, leading to increased levels of exposure to cosmic radiation.

Note 2: For the purpose of dose reconstruction, dose is calculated as an average over the mass of a specific tissue or organ. If a tissue is exposed to multiple sources of ionising radiation, the various dose estimates for each type of radiation must be combined.

2. Statements of Principles to be amended:

Statement of Principles concerning acoustic neuroma No. 29 of 2011

Statement of Principles concerning acoustic neuroma No. 30 of 2011

Statement of Principles concerning acute lymphoblastic leukaemia No. 75 of 2012, as amended

Statement of Principles concerning acute lymphoblastic leukaemia No. 76 of 2012

Statement of Principles concerning adenocarcinoma of the kidney No. 9 of 2013

Statement of Principles concerning adenocarcinoma of the kidney No. 10 of 2013

Statement of Principles concerning Alzheimer-type dementia No. 22 of 2010, as amended

Statement of Principles concerning angle-closure glaucoma No. 25 of 2012

Statement of Principles concerning angle-closure glaucoma No. 26 of 2012

Statement of Principles concerning aortic stenosis No. 21 of 2013

Statement of Principles concerning aortic stenosis No. 22 of 2013

Statement of Principles concerning atherosclerotic peripheral vascular disease No. 23 of 2012

Statement of Principles concerning atherosclerotic peripheral vascular disease No. 24 of 2012

Statement of Principles concerning carotid arterial disease No. 37 of 2012

Statement of Principles concerning carotid arterial disease No. 38 of 2012

Statement of Principles concerning cerebral meningioma No. 19 of 2009, as amended

Statement of Principles concerning cerebral meningioma No. 20 of 2009, as amended

```
Statement of Principles concerning cerebrovascular accident No. 65 of 2015
```

Statement of Principles concerning cerebrovascular accident No. 66 of 2015

Statement of Principles concerning chronic gastritis and chronic gastropathy No. 25 of 2013

Statement of Principles concerning chronic gastritis and chronic gastropathy No. 26 of 2013

Statement of Principles concerning chronic myeloid leukaemia No. 47 of 2014

Statement of Principles concerning chronic myeloid leukaemia No. 48 of 2014

Statement of Principles concerning chronic pancreatitis No. 104 of 2011

Statement of Principles concerning chronic pancreatitis No. 105 of 2011

Statement of Principles concerning erectile dysfunction No. 43 of 2013

Statement of Principles concerning erectile dysfunction No. 44 of 2013

Statement of Principles concerning fibrosing interstitial lung disease No. 53 of 2013

Statement of Principles concerning fibrosing interstitial lung disease No. 54 of 2013

Statement of Principles concerning gastric ulcer and duodenal ulcer No. 61 of 2015

Statement of Principles concerning gastric ulcer and duodenal ulcer No. 62 of 2015

Statement of Principles concerning goitre No. 23 of 2013

Statement of Principles concerning goitre No. 24 of 2013

Statement of Principles concerning Graves' disease No. 33 of 2013

Statement of Principles concerning Graves' disease No. 34 of 2013

Statement of Principles concerning Hashimoto's thyroiditis No. 31 of 2013

Statement of Principles concerning Hashimoto's thyroiditis No. 32 of 2013

Statement of Principles concerning heart block No. 1 of 2014

Statement of Principles concerning heart block No. 2 of 2014

Statement of Principles concerning hypothyroidism No. 29 of 2013

Statement of Principles concerning hypothyroidism No. 30 of 2013

Statement of Principles concerning malignant neoplasm of the bile duct No. 69 of 2015

Statement of Principles concerning malignant neoplasm of the bile duct No. 70 of 2015

Statement of Principles concerning malignant neoplasm of the bladder No. 96 of 2011

Statement of Principles concerning malignant neoplasm of the bladder No. 97 of 2011

Statement of Principles concerning malignant neoplasm of bone and articular cartilage No. 106 of 2011

Statement of Principles concerning malignant neoplasm of bone and articular cartilage No. 107 of 2011

Statement of Principles concerning malignant neoplasm of the breast No. 96 of 2014

Statement of Principles concerning malignant neoplasm of the breast No. 97 of 2014

Statement of Principles concerning malignant neoplasm of the cerebral meninges No. 21 of 2009, as amended

Statement of Principles concerning malignant neoplasm of the cerebral meninges No. 22 of 2009, as amended

Statement of Principles concerning malignant neoplasm of the colorectum No. 37 of 2013

Statement of Principles concerning malignant neoplasm of the colorectum No. 38 of 2013

Statement of Principles concerning malignant neoplasm of the liver No. 21 of 2011

Statement of Principles concerning malignant neoplasm of the liver No. 22 of 2011

Statement of Principles concerning malignant neoplasm of the lung No. 92 of 2014

Statement of Principles concerning malignant neoplasm of the lung No. 93 of 2014

Statement of Principles concerning malignant neoplasm of the ovary No. 70 of 2009, as amended

Statement of Principles concerning malignant neoplasm of the ovary No. 71 of 2009, as amended

Statement of Principles concerning malignant neoplasm of the renal pelvis and ureter No. 98 of 2011

Statement of Principles concerning malignant neoplasm of the renal pelvis and ureter No. 99 of 2011

Statement of Principles concerning malignant neoplasm of the salivary gland No. 57 of 2015

Statement of Principles concerning malignant neoplasm of the salivary gland No. 58 of 2015

Statement of Principles concerning malignant neoplasm of the stomach No. 58 of 2014 Statement of Principles concerning malignant neoplasm of the stomach No. 59 of 2014 Statement of Principles concerning malignant neoplasm of the thyroid gland No. 39 of 2014

Statement of Principles concerning malignant neoplasm of the thyroid gland No. 40 of 2014

Statement of Principles concerning malignant neoplasm of unknown primary site No. 80 of 2014

Statement of Principles concerning malignant neoplasm of unknown primary site No. 81 of 2014

Statement of Principles concerning multiple sclerosis No. 100 of 2011

Statement of Principles concerning myeloma No. 69 of 2012, as amended

Statement of Principles concerning narcolepsy No. 7 of 2014

Statement of Principles concerning narcolepsy No. 8 of 2014

Statement of Principles concerning neoplasm of the pituitary gland No. 53 of 2015

Statement of Principles concerning non-aneurysmal aortic atherosclerotic disease No. 15 of 2012

Statement of Principles concerning non-aneurysmal aortic atherosclerotic disease No. 16 of 2012

Statement of Principles concerning non-Hodgkin's lymphoma No. 28 of 2010, as amended

Statement of Principles concerning open-angle glaucoma No. 27 of 2012

Statement of Principles concerning open-angle glaucoma No. 28 of 2012

Statement of Principles concerning osteomyelitis No. 90 of 2014

Statement of Principles concerning osteomyelitis No. 91 of 2014

Statement of Principles concerning otitis externa No. 58 of 2012

Statement of Principles concerning otitis externa No. 59 of 2012

Statement of Principles concerning otitis media No. 51 of 2014

Statement of Principles concerning otitis media No. 52 of 2014

Statement of Principles concerning renal artery atherosclerotic disease No. 102 of 2011

Statement of Principles concerning renal artery atherosclerotic disease No. 103 of 2011

Statement of Principles concerning soft tissue sarcoma No. 5 of 2015

Statement of Principles concerning soft tissue sarcoma No. 6 of 2015

Statement of Principles concerning tinnitus No. 33 of 2012

Statement of Principles concerning tinnitus No. 34 of 2012

Part 2—Amendments of clause 1 of Schedule 1 to certain Statements of Principles

1. Amendments of definition

Omit the definition of *cumulative equivalent dose* in clause 1 of Schedule 1 to the Statements of Principles to be amended as listed in paragraph 2 of this Part and substitute:

cumulative equivalent dose means the total dose of ionising radiation received by the particular organ or tissue from external exposure, internal exposure or both, apart from normal background radiation exposure in Australia, calculated in accordance with the methodology set out in *Guide to calculation of 'cumulative equivalent dose' for the purpose of applying ionising radiation factors contained in Statements of Principles determined under Part XIA of the Veterans' Entitlements Act 1986 (Cth)*, Australian Radiation Protection and Nuclear Safety Agency, as in force on 2 August 2017.

Note 1: Examples of circumstances that might lead to exposure to ionising radiation include being present during or subsequent to the testing or use of nuclear weapons, undergoing diagnostic or therapeutic medical procedures involving ionising radiation, and being a member of an aircrew, leading to increased levels of exposure to cosmic radiation.

Note 2: For the purpose of dose reconstruction, dose is calculated as an average over the mass of a specific tissue or organ. If a tissue is exposed to multiple sources of ionising radiation, the various dose estimates for each type of radiation must be combined.

2. Statements of Principles to be amended:

Statement of Principles concerning acquired cataract (Reasonable Hypothesis) (No. 87 of 2016)

Statement of Principles concerning acquired cataract (Balance of Probabilities) (No. 88 of 2016)

Statement of Principles concerning acute myeloid leukaemia (No. 71 of 2015), as amended

Statement of Principles concerning acute myeloid leukaemia (No. 72 of 2015), as amended

Statement of Principles concerning benign neoplasm of the eye and adnexa (Reasonable Hypothesis) (No. 41 of 2016)

Statement of Principles concerning benign neoplasm of the eye and adnexa (Balance of Probabilities) (No. 42 of 2016)

Statement of Principles concerning cardiomyopathy (No. 85 of 2015)

Statement of Principles concerning cardiomyopathy (No. 86 of 2015)

Statement of Principles concerning cirrhosis of the liver (Reasonable Hypothesis) (No. 1 of 2017)

Statement of Principles concerning external burn (Reasonable Hypothesis) (No. 110 of 2015)

Statement of Principles concerning external burn (Balance of Probabilities) (No. 111 of 2015)

Statement of Principles concerning ischaemic heart disease (Reasonable Hypothesis) (No. 1 of 2016)

Statement of Principles concerning ischaemic heart disease (Balance of Probabilities) (No. 2 of 2016)

Statement of Principles concerning malignant neoplasm of the brain (Reasonable Hypothesis) (No. 85 of 2016)

Statement of Principles concerning malignant neoplasm of the brain (Balance of Probabilities) (No. 86 of 2016)

Statement of Principles concerning malignant neoplasm of the endometrium (Reasonable Hypothesis) (No. 11 of 2016)

Statement of Principles concerning malignant neoplasm of the endometrium (Balance of Probabilities) (No. 12 of 2016)

Statement of Principles concerning malignant neoplasm of the gallbladder (No. 89 of 2015)

Statement of Principles concerning malignant neoplasm of the gallbladder (No. 90 of 2015)

Statement of Principles concerning malignant neoplasm of the oesophagus (Reasonable Hypothesis) (No. 120 of 2015), as amended

Statement of Principles concerning malignant neoplasm of the oesophagus (Balance of Probabilities) (No. 121 of 2015)

Statement of Principles concerning mesothelioma (Reasonable Hypothesis) (No. 104 of 2015)

Statement of Principles concerning mesothelioma (Balance of Probabilities) (No. 105 of 2015)

Statement of Principles concerning myelodysplastic syndrome (No. 73 of 2015), as amended

Statement of Principles concerning myelodysplastic syndrome (No. 74 of 2015), as amended

Statement of Principles concerning non-melanotic malignant neoplasm of the skin (Reasonable Hypothesis) (No. 7 of 2016)

Statement of Principles concerning non-melanotic malignant neoplasm of the skin (Balance of Probabilities) (No. 8 of 2016)

Statement of Principles concerning optochiasmatic arachnoiditis (Reasonable Hypothesis) (No. 57 of 2016)

Statement of Principles concerning optochiasmatic arachnoiditis (Balance of Probabilities) (No. 58 of 2016)

Statement of Principles concerning peritoneal adhesions (Reasonable Hypothesis) (No. 3 of 2016)

Statement of Principles concerning peritoneal adhesions (Balance of Probabilities) (No. 4 of 2016)

Statement of Principles concerning trigeminal neuropathy (No. 79 of 2015)

Statement of Principles concerning trigeminal neuropathy (No. 80 of 2015)